1455 related articles for article (PubMed ID: 26966191)
1. MYC regulates the antitumor immune response through CD47 and PD-L1.
Casey SC; Tong L; Li Y; Do R; Walz S; Fitzgerald KN; Gouw AM; Baylot V; Gütgemann I; Eilers M; Felsher DW
Science; 2016 Apr; 352(6282):227-31. PubMed ID: 26966191
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
[TBL] [Abstract][Full Text] [Related]
3. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
5. Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy.
Li Y; Meng X; Chen G; Hou Y; Wu X; Wang J; Cong X; Mao K; Wu C; Chen H; Sun X; Zhou J; Wang Y; Yang YG; Sun T
Biomater Sci; 2022 Nov; 10(23):6755-6767. PubMed ID: 36301154
[TBL] [Abstract][Full Text] [Related]
6. The MYC oncogene is a global regulator of the immune response.
Casey SC; Baylot V; Felsher DW
Blood; 2018 May; 131(18):2007-2015. PubMed ID: 29514782
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
Qu S; Jiao Z; Lu G; Yao B; Wang T; Rong W; Xu J; Fan T; Sun X; Yang R; Wang J; Yao Y; Xu G; Yan X; Wang T; Liang H; Zen K
Genome Biol; 2021 Apr; 22(1):104. PubMed ID: 33849634
[TBL] [Abstract][Full Text] [Related]
8. MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells.
Zou J; Zhuang M; Yu X; Li N; Mao R; Wang Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Mol Immunol; 2018 Sep; 101():203-209. PubMed ID: 30007230
[TBL] [Abstract][Full Text] [Related]
9. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
10. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Kim EY; Kim A; Kim SK; Chang YS
Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
[TBL] [Abstract][Full Text] [Related]
11. Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression.
Gong J; Ji Y; Liu X; Zheng Y; Zhen Y
Biochem Pharmacol; 2022 Mar; 197():114894. PubMed ID: 34968486
[TBL] [Abstract][Full Text] [Related]
12. MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47.
Huang W; Wang WT; Fang K; Chen ZH; Sun YM; Han C; Sun LY; Luo XQ; Chen YQ
Mol Cancer; 2018 Jan; 17(1):12. PubMed ID: 29368647
[TBL] [Abstract][Full Text] [Related]
13. Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma.
Kawamura A; Kawamura T; Riddell M; Hikita T; Yanagi T; Umemura H; Nakayama M
Cancer Sci; 2019 May; 110(5):1780-1789. PubMed ID: 30801864
[TBL] [Abstract][Full Text] [Related]
14. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
Xue T; Wang WG; Zhou XY; Li XQ
Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
[TBL] [Abstract][Full Text] [Related]
15. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
[TBL] [Abstract][Full Text] [Related]
16. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
18. Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines.
Ma C; Horlad H; Pan C; Yano H; Ohnishi K; Fujiwara Y; Matsuoka M; Lee A; Niidome T; Yamanaka R; Takeya M; Komohara Y
J Clin Exp Hematop; 2017 Jul; 57(1):21-25. PubMed ID: 28496056
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D
Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of low-dose radiation-induced upregulation of immune checkpoint molecule expression in lung cancer cells.
Wan X; Fang M; Chen T; Wang H; Zhou Q; Wei Y; Zheng L; Zhou Y; Chen K
Biochem Biophys Res Commun; 2022 Jun; 608():102-107. PubMed ID: 35397421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
